

# News Release

Solasia Pharma K.K.

3F, Shiodome Building  
1-2-20 Kaigan Minato-ku  
Tokyo 105-0022 Japan  
Tel + 81 3 6721 8332  
Fax + 81 3 6721 2020  
[www.solasia.co.jp](http://www.solasia.co.jp)

The Solasia logo is written in a red, serif font.

## **Solasia Pharma and Kyowa Hakko Kirin enter into a License Agreement for SP-01 (Sancuso®) in Asia**

Tokyo, Japan March 3, 2010 – Solasia Pharma K.K. (<http://www.solasia.co.jp>), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the signing of a License and Supply Agreement with Kyowa Hakko Kirin that provides Kyowa Hakko Kirin with an exclusive right to market and sell SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Taiwan, Hong Kong, Singapore and Malaysia.

Under the terms of the agreement, Solasia will receive upfront, regulatory and sales milestones. Kyowa Hakko Kirin will be responsible for all commercialization activities in Taiwan, Hong Kong, Singapore and Malaysia. Solasia will supply product to Kyowa Hakko Kirin in these territories.

Sancuso is the first and only commercialized extended release granisetron transdermal product. In May 2008, Solasia acquired the exclusive right to Sancuso from ProStrakan Group plc. ([www.prostrakan.com](http://www.prostrakan.com)) for Japan, China, and other territories in Asia. Solasia retains full rights in Japan and China where it is currently conducting Sancuso clinical development activities. Sancuso was approved in the United States in September 2008 for the prevention of chemotherapy-induced nausea and vomiting.

“We are very excited to build upon our strong relationship with Kyowa Hakko Kirin, and look forward to seeing Sancuso launched in these Asian territories in the near future,” stated Solasia President Steve Engen.

### **About Sancuso**

Sancuso is an extended release transdermal system, delivering the anti-emetic, granisetron, steadily into the patient’s bloodstream over several days without the need for injections or swallowing pills. Granisetron is a 5-HT<sub>3</sub> receptor antagonist with well-established efficacy against chemotherapy-induced nausea and vomiting (CINV). Sancuso was approved by the U.S. Food & Drug Administration (FDA) on September 12, 2008 for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days. ProStrakan launched Sancuso in the U.S. in the fourth quarter of 2008. Patents protecting Sancuso have been granted in the EU (2007), Japan (2008), and the US (2009).

---

Contact

Steve Engen, President  
Tel: +81-(0)3-6721-8332 e-mail: [sengen@solasia.co.jp](mailto:sengen@solasia.co.jp)

# News Release

Solasia Pharma K.K.

3F, Shiodome Building  
1-2-20 Kaigan Minato-ku  
Tokyo 105-0022 Japan  
Tel + 81 3 6721 8332  
Fax + 81 3 6721 2020  
[www.solasia.co.jp](http://www.solasia.co.jp)

The Solasia logo is written in a red, serif font.

## **About Solasia**

Solasia Pharma K.K. (Tokyo, Japan) was formed in November 2006 by MPM Capital and Itochu Corporation to address unmet needs for important new Western oncology therapies throughout Asia. Our mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. In May 2008, Solasia acquired Asia rights to Sancuso (granisetron transdermal patch) from ProStrakan Group plc. To date, Solasia has raised approximately \$16 million in Series A financing.

## **About Kyowa Hakko Kirin**

Kyowa Hakko Kirin Co., Ltd. is a life science company and aims to become a global specialty pharmaceutical company based in Japan which contributes to health and well-being of people around the world by discovering innovative novel drugs with the state-of-the-art biotechnology focused on antibody mainly in the areas of cancer, renal diseases and immunology and by conducting development and commercialization of the drugs globally.